TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2032492
Drug: Autologous LAK
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous LAK cell reinfusion treatment for 6 weeks
Study: 2032492
Drug: 10% glucose
Normalized name: Dextrose 10% Oral Solution [SIMILAC 10% GLUCOSE WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% glucose solution intravenous drip for 6 weeks
Study: 7226903
Drug: High-dose theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose theophylline
Study: 7226903
Drug: Fenoterol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (10 mg)
Study: 7226903
Drug: Low-dose theophylline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose theophylline (130 mg)
Study: 7226903
Drug: Low-dose theophylline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose theophylline (130 mg) + fenoterol (5 mg)
Study: 19081652
Drug: Arm A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: Paclitaxel 200 mg/m2 and carboplatin AUC6 with accelerated radiotherapy 1.7 Gy BID to 64.6 Gy in 4.5 weeks.
Study: 19081652
Drug: Arm B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: Daily concomitant paclitaxel 12 mg/m2 with conventionally fractionated radiotherapy 2 Gy to 60 Gy in 6 weeks.
Study: 19081652
Drug: Arm C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm C: Weekly concomitant paclitaxel 60 mg/m2 and identical radiotherapy to 60 Gy.
Study: 19081652
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group not specified as there are three treatment arms.
Study: 17868210
Drug: Boiled extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boiled extract of Nigella sativa (15 mL/kg of 0.1 g%)
Study: 15115259
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of vitamin B6 daily and one monthly injection of 200 microg vitamin B12, plus 15 mg folic acid daily (group A)
Study: 15115259
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of vitamin B6 daily and one monthly injection of 1,000 microg vitamin B12, plus 15 mg folic acid daily (group B)
Study: 7483616
Drug: Proajmaline (neogilurytmal)
Normalized name: prajmaline
DrugBank: Prajmaline (DB13555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proajmaline (neogilurytmal) 3 x 20 mg
Study: 7483616
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (neogilurytmal 2 x 20 mg and magnesium 2 x 0.6)
Study: 3190993
Drug: Allopurinol 50
Normalized name: allopurinol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 50 mg daily
Study: 6847424
Drug: Allopurinol 100
Normalized name: allopurinol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 100 mg daily
Study: 3190993
Drug: Allopurinol 600
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol 600 mg daily
Study: 3190993
Drug: Allopurinol (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (various doses)
Study: 123426
Drug: Leukocytic interferon
Normalized name: interferon alfa-3n,human leukocyte derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocytic interferon with metacyl (0.25 ml once a day)
Study: 31076203
Drug: 500 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 μg of nemiralisib via Ellipta dry powder inhaler
Study: 31076203
Drug: 750 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 μg of nemiralisib via Ellipta dry powder inhaler
Study: 26964165
Drug: Tamsulosin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.2 mg, twice a day for 1 month)
Study: 22924409
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg once daily for 5 days (n = 48)
Study: 22924409
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg administered 24 h post-warfarin
Study: 18294998
Drug: Idraparinux (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idraparinux (2.5 mg weekly)
Study: 18294998
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonists (adjusted-dose, target INR 2-3)
Study: 12641543
Drug: Topical 5‐ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5‐ASA 2 g and 80 mM L‐1 sodium‐butyrate bid (Group A)
Study: 12641543
Drug: 5‐ASA 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐ASA 2 g and 80 mL saline bid (Group B)
Study: 10637255
Drug: ACE chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE chemotherapy every 2 weeks with G-CSF support
Study: 10637255
Drug: ACE chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE chemotherapy every 3 weeks (control group)
Study: 7908879
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no H2 receptor antagonist)
Study: 16417414
Drug: Other sex
Normalized name: Other sex hormones and modulators of the genital system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other sex steroid levels (estrone, total estradiol, total testosterone)
Study: 12716250
Drug: THC (delta‐9‐tetrahydrocannabinol)
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC (delta‐9‐tetrahydrocannabinol) up to 10 mg/day for 6 weeks
Study: 10793162
Drug: Ventilation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventilation with lower tidal volumes (initial tidal volume of 6 ml per kilogram of predicted body weight, plateau pressure of 30 cm of water or less)
Study: 10793162
Drug: Traditional ventilation
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional ventilation treatment (initial tidal volume of 12 ml per kilogram of predicted body weight, plateau pressure of 50 cm of water or less)
Study: 9489309
Drug: Ketorolac (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (30 mg i.v.) administered immediately after induction and for postoperative analgesia beginning at skin closure
Study: 9489309
Drug: No ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ketorolac administered before the operation, postoperative treatment same as intervention group
Study: 22290668
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg caffeine in de-caffeinated coffee
Study: 3899404
Drug: Dipyridamole-aspirin
Normalized name: aspirin / dipyridamole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole-aspirin
Study: 3899404
Drug: Pentoxifylline-aspirin
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline-aspirin
Study: 31465307
Drug: Inspiratory Muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory Muscle Training (IMT) performed twice daily for 4 weeks starting 3 days after surgery
Study: 29504328
Drug: Dexamethasone 8mg
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 8mg intravenously preoperatively and second dose 4 hours postoperatively
Study: 26827617
Drug: Feedback-incentive (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feedback-incentive (monthly letter with social norm feedback plus small financial incentive for increasing green purchases)
Study: 26827617
Drug: Feedback-only (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feedback-only (monthly letter with social norm feedback about healthy food purchases)
Study: 22693239
Drug: CHO‐PRO solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO‐PRO solution (1.2 g CHO/kg body mass and 0.4 g PRO/kg body mass)
Study: 22693239
Drug: CHO‐PRO solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO‐PRO solution
Study: 22693239
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (CON)
Study: 18375410
Drug: Diane(35) Diario
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diane(35) Diario (35 mg ethinyl-estradiol plus 2 mg cyproterone acetate)
Study: 11672911
Drug: BCG vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccination before last DTP vaccine
Study: 11672911
Drug: Antimalarials within
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimalarials within last week
Study: 7961349
Drug: Therapy received
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy received by 65% of abused children for an average of 9 months.
Study: 3298694
Drug: Bacillus Calmette-Guerin
Normalized name: BACILLUS CALMETTE-GUERIN VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette-Guerin therapy with quarterly maintenance instillations
Study: 3298694
Drug: Bacillus Calmette-Guerin
Normalized name: BACILLUS CALMETTE-GUERIN VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus Calmette-Guerin therapy without maintenance instillations
Study: 3298694
Drug: Maintenance bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance bacillus Calmette-Guerin therapy
Study: 21167334
Drug: Platelet function
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet function monitoring with dose adjustment in suboptimal responders
Study: 21167334
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of dual antiplatelet therapy beyond 1 year
Study: 21167334
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care without monitoring and without dose adjustment
Study: 9039228
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus adjuvant chemotherapy (cyclophosphamide, vincristine and prednisone)
Study: 1357681
Drug: CGP 361
Normalized name: Leucoflex CGP KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGP 361 A (beta-blocking drug)
Study: 1357681
Drug: Flupenthixol (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupenthixol (low-dose neuroleptic)
Study: 29934046
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (0.5, 1, and 2 g daily)
Study: 27239991
Drug: Cytoflavin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin (2 tabs. 2 times a day for 25 days) + cognitive therapy
Study: 12860497
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by Galantamine 24 mg/d
Study: 2004540
Drug: Liquid formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation (1.67 mg/ml)
Study: 2004540
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tablet (2 x 200 mg)
Study: 2004540
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg tablet
Study: 6439360
Drug: Theophylline (200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (200, 400, 600, and 800 mg)
Study: 29454514
Drug: Intermittent linsitinib
Normalized name: Linsitinib
DrugBank: Linsitinib (DB06075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent linsitinib (600mg once daily on Days 1-3 per week) with paclitaxel (80mg/m2 on Days 1, 8, and 15)
Study: 29454514
Drug: Continuous linsitinib
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous linsitinib (150mg twice daily) with paclitaxel (80mg/m2 on Days 1, 8, and 15)
Study: 26857248
Drug: Balneotherapy (BT)
Normalized name: BTS
DrugBank: Pyruvic acid (DB00119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balneotherapy (BT) in addition to physical therapy (PT)
Study: 24172160
Drug: Levomilnacipran ER
Normalized name: levomilnacipran Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levomilnacipran ER 75 or 100 mg/day
Study: 17311014
Drug: Pharmacy technician‐led
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacy technician‐led medication review and counselling clinic
Study: 11593218
Drug: 3-minute adenosine
Normalized name: adenosine 3 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-minute adenosine infusion at 140 microg/kg per minute
Study: 11593218
Drug: 6-minute adenosine
Normalized name: adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-minute adenosine infusion at 140 microg/kg per minute
Study: 9638504
Drug: Lysine clonixinate
Normalized name: lysine clonixinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine clonixinate (125 mg tablet every 4 h for 2 days)
Study: 9638504
Drug: Paracetamol/codeine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol/codeine (500 mg + 30 mg every 4 h for 2 days)
Study: 9638504
Drug: Paracetamol/codeine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol/codeine (500 mg + 30 mg)
Study: 9638504
Drug: Lysine clonixinate
Normalized name: lysine clonixinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine clonixinate (125 mg)
Study: 1138844
Drug: Intravenous Diamox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Diamox with variable doses of Pilocarpine
Study: 27299461
Drug: Nebulization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulization of Shenmai Injection (0.6 mL/kg in 10 mL normal saline)
Study: 27299461
Drug: Intravenous drip
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drip of Shenmai Injection (0.6 mL/kg dissolved in 250 mL of 10% glucose)
Study: 17160910
Drug: DPP IV
Normalized name: L-DPPG-Na
DrugBank: Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DB14105)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPP IV inhibitors (gliptins)
Study: 12532097
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily
Study: 12532097
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 250 microg administered twice daily
Study: 11233712
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of azelastine and beclomethasone administered together (morning and evening, with a 5-minute interval)
Study: 11233712
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of azelastine and beclomethasone administered separately (azelastine in the morning and evening, beclomethasone later during the morning and in the afternoon)
Study: 11233712
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of azelastine and beclomethasone
Study: 8895908
Drug: 89Sr (148
Approvals — FDA: no, EMA: no, PMDA: no
Description: 89Sr (148 MBq) followed by carboplatin (100 mg m‐2 at 7 and 21 days)
Study: 1900379
Drug: deferoxamine (chelation
Approvals — FDA: no, EMA: no, PMDA: no
Description: deferoxamine (chelation therapy)
Study: 1900379
Drug: no chelation
Approvals — FDA: no, EMA: no, PMDA: no
Description: no chelation therapy (control group)
Study: 31764095
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral tenofovir disoproxil fumarate (TDF) for preexposure prophylaxis (PrEP)
Study: 24747867
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with peginterferon alfa-2a 135 μg/week plus ribavirin 200 mg/day (n=86)
Study: 24747867
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a 135 μg/week (n=86)
Study: 24473718
Drug: Low-fluoride dentifrices
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fluoride dentifrices (0-275, 275-550, 550-1,100 µg F/g)
Study: 24473718
Drug: Low-fluoride dentifrices
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fluoride dentifrices (1,100 µg F/g)
Study: 10934930
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) with propofol and midazolam coinduction
Study: 9058494
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid administered intravenously at the end of the operation, repeated three hours later.
Study: 9058494
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered to control group.
Study: 27055643
Drug: Saline (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.1 ml/kg)
Study: 21934521
Drug: Lipo‐PGE1 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipo‐PGE1 (20 μg/day intravenously for 5 days)
Study: 16941968
Drug: Comprehensive program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive program of physical therapy
Study: 14570664
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine sulfate (ITMS) 0.1 mg
Study: 14570664
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine sulfate (ITMS) 0.2 mg
Study: 14570664
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine sulfate (ITMS) 0.3 mg
Study: 14570664
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine sulfate (ITMS) 0.0 mg (control)
Study: 14570664
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine sulfate (ITMS) (0.1, 0.2, 0.3 mg)
Study: 14570664
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine sulfate (ITMS) (0.2 mg)
Study: 10761163
Drug: Acetaminophen controlled-release
Normalized name: acetaminophen Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen controlled-release (CR) sprinkles on applesauce
Study: 10761163
Drug: Acetaminophen immediate-release
Normalized name: acetaminophen Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen immediate-release (IR) elixir
Study: 8881732
Drug: Chemotherapy (epirubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (epirubicin, cisplatin, and 5‐fluorouracil)
Study: 1553892
Drug: Bepridil hydrochloride
Normalized name: Bepridil Hydrochloride
DrugBank: Bepridil (DB01244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bepridil hydrochloride (HCl) at a mean maintenance dosage of 324 mg/day
Study: 3296615
Drug: DDS 100
Normalized name: DDS
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DDS 100 mg 7/7 for 3 years
Study: 3296615
Drug: RMP 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMP 900 mg 1/7 for 8 doses
Study: 3296615
Drug: RMP 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMP 900 mg 7/7 for 12 doses
Study: 29551889
Drug: β‐asarone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐asarone 10 mg/d, tenuigenin 10 mg/d, and memantine 5‐20 mg/d
Study: 29551889
Drug: memantine 5‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: memantine 5‐20 mg/d
Study: 15704687
Drug: Qianlie Sanyu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qianlie Sanyu Capsule
Study: 8077472
Drug: Topical propylthiouracil
Normalized name: Propylthiouracil
DrugBank: Propylthiouracil (DB00550)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical propylthiouracil (PTU), applied three times daily for 4 to 8 weeks
Study: 1087743
Drug: Ketoprofen (KETO),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (KETO), 200 mg daily
Study: 1087743
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA), 3.6 g daily
Study: 26652797
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of quadrivalent HPV vaccine on days 1, 60, and 180 or later
Study: 26652797
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of quadrivalent HPV vaccine on days 1 and 180 or later
Study: 26652797
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of quadrivalent HPV vaccine on days 1 and 60 by default
Study: 26652797
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of quadrivalent HPV vaccine by default
Study: 24613188
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg sildenafil citrate
Study: 20633189
Drug: Active eradication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active eradication therapy
Study: 12442020
Drug: 9-valent pneumococcal
Normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-valent pneumococcal conjugate vaccine (n = 250)
Study: 10373132
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 1 mg twice daily for three nights and 500 microg twice daily for 11 nights
Study: 21624883
Drug: HibMenCY vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HibMenCY vaccine
Study: 21624883
Drug: Hib conjugate
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hib conjugate vaccine (ActHIB) and PedvaxHIB
Study: 16454149
Drug: Specific acupressure
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific acupressure treatment
Study: 16454149
Drug: Placebo acupressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo acupressure treatment
Study: 11731064
Drug: 1.0mg morphine-HCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0mg morphine-HCl
Study: 11731064
Drug: 0.1mg morphine-HCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1mg morphine-HCl
Study: 9041945
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rHuGH) for 1 year